1-6 of 6
Lijun Xia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5323: Accelerating the drug discovery process with an automated high-throughput protein production and characterization platform for AI-driven antibody development of immunotherapy

Zhehao Xiong, Wei Jiang, Lijun Xia, Jianhua Huang, Cheng-chi Chao
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5323.
https://doi.org/10.1158/1538-7445.AM2023-5323
Published: 04 April 2023
View article titled, Abstract 5323: Accelerating the drug discovery process with an automated high-throughput protein production and characterization platform for AI-driven antibody development of immunotherapy
Journal Articles

Abstract 5801: Loss of core 1 β1,3-galactosyltransferase (C1GALT1) in pancreatic cancer leads to altered mucin glycosylation and increased tumor aggressiveness

Seema Chugh, Satyanarayana Rachagani, Xinheng Yu, Sriram Neelamegham, Lijun Xia, Michel M. Ouellette, Moorthy P. Ponnusamy, Surinder K. Batra
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5801.
https://doi.org/10.1158/1538-7445.AM2017-5801
Published: 01 July 2017
View article titled, Abstract 5801: Loss of core 1 β1,3-galactosyltransferase (C1GALT1) in pancreatic cancer leads to altered mucin glycosylation and increased tumor aggressiveness
Journal Articles

Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

Kai Song, Brett H. Herzog, Minjia Sheng, Jianxin Fu, J. Michael McDaniel, Jia Ruan, Lijun Xia
Journal: Cancer Research
Cancer Res (2013) 73 (24): 7254–7264.
https://doi.org/10.1158/0008-5472.CAN-13-0750
Published: 16 December 2013
View article titled, Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma
Open the PDF for Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2833: Functional cross-talk between the Wnt and Notch pathways regulate hyperplasia and/or colitis in response to bacterial infection

Ishfaq Ahmed, Parthasarathy Chandrakesan, Sandra Mccoy, Lijun Xia, Shahid Umar
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2833.
https://doi.org/10.1158/1538-7445.AM2011-2833
Published: 15 April 2011
View article titled, Abstract 2833: Functional cross-talk between the Wnt and Notch pathways regulate hyperplasia and/or colitis in response to bacterial infection
Journal Articles

Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model

James C. Cusack, Jr, Rong Liu, Lijun Xia, David Ljungman, Rena Bahjat, Michael A. Palladino, Jr
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1167.
Published: 01 May 2005
View article titled, Oral proteasome inhibitor (NPI-0052) enhances sensitivity to combination Gemcitabine and Erbitux in a pancreatic cancer xenograft model
Journal Articles

Drug resistance in a sarcoma xenograft model is overcome by schedule-dependent proteasome inhibition using Velcade™ (Bortezomib, formerly PS-341).

David Ljungman, John Flannery, Rong Liu, Lijun Xia, Julian Adams, Peter Elliott, Margaret Read, Oscar Kashala, James C. Cusack
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 491.
Published: 01 April 2004
View article titled, Drug resistance in a sarcoma xenograft model is overcome by schedule-dependent proteasome inhibition using Velcade<sup>™</sup> (Bortezomib, formerly PS-341).